Bluebird bio Long Term Debt

Bluebird bio (BLUE) currently reports a long-term debt of $39M as of March 2025. That compares with $210M in the prior-year period — down 81.3% year over year. Use the charts on this page to explore Bluebird bio's long-term debt history and peer comparisons.

Bluebird bio's long-term debt decreased from $210M to $39M — a 81.3% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bluebird bio reported $39M in long-term debt as of March 2025. That compares with $210M in the prior-year period — down 81.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $39M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bluebird bio, and consider following BLUE for alerts when major investors trade the stock.

Bluebird bio is classified in the Healthcare sector. On long-term debt, it currently shows $39M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLUE with unrelated industries.